Navigation Links
Vasogen Provides an Update on ACCLAIM-II Preparations
Date:12/17/2007

MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today provided an update on ACCLAIM-II, a confirmatory clinical trial which is designed to support an application for US market approval of the Celacade(TM) System for the treatment of patients with NYHA Class II heart failure.

The Company has been working diligently on the ACCLAIM-II study, including the establishment of a Steering Committee led by James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure; appointing Chairs for the Data and Safety Monitoring Board (DSMB) and Central Endpoint Committee (CEC); developing the study protocol, CEC adjudication plans, and other key trial documents, such as case report forms and informed consent forms; and selecting a contract research organization to assist with study execution.

Concurrent with the preparations for ACCLAIM-II, Vasogen has been working closely with the U.S. Food and Drug Administration (FDA) to finalize the protocol and the statistical analysis plan for the study using a Bayesian approach and adaptive clinical design. The planned study design indicates that as few as 300 patients could provide sufficient data to confirm the finding in the pre-specified sub-group of ACCLAIM patients with NYHA Class II heart failure. Furthermore, the use of an adaptive clinical trial design also provides the flexibility to increase the sample size up to 600 patients, should additional data be required. The ACCLAIM trial demonstrated a 39% reduction (p=0.0003) in the risk of death and cardiovascular hospitalizations for the large pre-specified subgroup of 689 NYHA class II heart failure patients.

In preparation
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. CardioDynamics Provides 2007 Shareholder Meeting Update
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. NxStage Medical Provides Update on Medisystems Acquisition
7. VaxGen Files 2006 Financial Statements and Provides Cash Update
8. Signalife Provides Corporate Update
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
11. SGX Provides Update on BCR-ABL Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... of three large odour control systems for waste water treatment ... orders are consistent with the market resurgence in ... and CEO. "After a difficult period of restraint in our ... see sales growth. Our lower cost structure, technology improvements and ...
(Date:9/2/2014)... Melbourne, Victoria, Australia (PRWEB) September 02, 2014 ... may provide a cure for chronic tinnitus are seeking ... campaign, run on the Indiegogo platform ( http://igg.me/at/tinaway ), ... designed to be a therapeutic ‘mHealth’ app and is ... the brainchild of a team of biomedical and software ...
(Date:8/31/2014)... Wockhardt Limited today announces a major boost ... when two of its drugs, WCK 771 and WCK ... status from U.S. Food & Drug Administration (FDA).  QIDP ... which have a high degree of unmet need in ... Control (a top U.S. government health and safety body). ...
(Date:8/30/2014)... The Global and China Electrical ... study on the current state of the Electrical ... The report provides a basic overview of the ... Global market analysis and Chinese domestic market analysis ... trends and competitive landscape of the market. A ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ("Angiotech") (NASDAQ: ... and medical device company, today announced that ... (the "Tender Offer"),for its outstanding Senior Floating ... "First Priority Notes"), and its outstanding 7.75% ...
... breadth of experience and business expertise, SCOTTSDALE, ... technology company that markets the Provant(R) Wound Therapy,System, ... its Board of,Directors. The two new directors are ... and Charles "Chuck" S. Lunden, a principal with,Bederson ...
... ... the job done, NEWARK, N.J., Aug. 22 BioNeutral announced ... its,Ogiene(TM) FE technology to bring 10,000 mobile homes into full compliance,so ... in need,of biohazard-free housing., Dr. Andy Kielbania, Chief Scientist at ...
Cached Biology Technology:Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 2Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 3Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 4Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014 5Regenesis Biomedical Announces Additions to Board of Directors 2BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana 2
(Date:9/1/2014)... MA ─ Dietary quality in the U.S. has improved ... trans fat intakebut overall dietary quality remains poor and ... according to a new study from Harvard School of ... direct evidence to date that the extensive efforts by ... are having some payoff, but it also indicates that ...
(Date:9/1/2014)... BOSTON (September 1, 2014, 10:20 AM EDT) It ... healthy low-calorie foods over unhealthy higher-calorie foods, according to ... Human Nutrition Research Center on Aging (USDA HNRCA) at ... today in the journal Nutrition & Diabetes , ... suggests that it is possible to reverse the addictive ...
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... new study finds that Caribbean seaweeds are far better competitors ... this triumph is bad news for Caribbean coral reefs. ... the living corals that build reefs and contribute startling white ... environment but in fact a battle is constantly waged between ...
... Obama has made cyber security an integral issue when ... ensure that the U.S. remains on the cutting edge, ... will convene a gathering of the nation,s top minds ... issues affecting the economy and United States, national security. ...
... Smith, Ph.D., Wellcome Trust Principal Research Fellow and ... Fellow of Emmanuel College, Cambridge, has been bestowed ... Award, recognizing exemplary leadership in the international microbiological ... University of Virginia, says Smith is "internationally recognized ...
Cached Biology News:Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 2Jim Demitrieus, CEO of EyeLock, Invited to White House Cyber Security Event 3The American Society for Microbiology honors Geoffrey L. Smith 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
...
...
Biology Products: